ASTRAZEN
AstraZeneca Pharma India Limited (ASTRAZEN) Stock Analysis
AstraZeneca Pharma India Limited is the Indian subsidiary of AstraZeneca, marketing innovative medicines in oncology, cardio-metabolic, and respiratory therapies. It sells patented and partnered brands to hospitals and specialists in India. The company focuses on high-value prescription pharmaceuticals. It is a listed large-cap MNC pharma stock.
Healthcare › Drug Manufacturers - Specialty & Generic
₹5,970.50
+2.29% 1W | -35.20% 52W
Market Cap
14.9k CR
P/E Ratio
88
52W High
₹9849.5
52W Low
₹5640
Div. Yield
0.61%
Beta
0.2
50 DMA
₹6854.5
200 DMA
₹8023.6
Profit Margin
7%
Inst. Own.
9.2%
📊 ANALYZING TREND
✅ BOUNCE FROM SUPPORT
Fundamentals
Profit & Loss
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 295 | 311 | 306 | 383 | 388 | 408 | 440 | 480 | 526 | 559 | 612 | 579 | 683 |
| Expenses | 228 | 258 | 291 | 334 | 349 | 355 | 363 | 394 | 445 | 484 | 567 | 518 | 634 |
| Operating Profit | 67 | 53 | 15 | 49 | 38 | 53 | 77 | 86 | 81 | 75 | 45 | 61 | 49 |
| OPM % | 23% | 17% | 4.9% | 13% | 10% | 13% | 17% | 18% | 15% | 13% | 7% | 11% | 7% |
| Other Income | 8 | 25 | 10 | 9 | -49 | 8 | -26 | 10 | 11 | 1 | 7 | 5 | 9 |
| Interest | 0 | 0 | 1 | -0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 2 | 2 |
| Depreciation | 4 | 4 | 4 | 4 | 4 | 9 | 9 | 18 | 17 | 3 | 4 | 6 | 5 |
| Profit before tax | 71 | 73 | 20 | 54 | -15 | 51 | 42 | 78 | 75 | 73 | 47 | 58 | 51 |
| Tax % | 25% | 29% | 23% | 27% | -22% | 25% | 27% | 26% | 25% | 26% | 30% | 23% | 25% |
| Net Profit | 54 | 52 | 16 | 39 | -12 | 38 | 31 | 58 | 56 | 54 | 33 | 45 | 38 |
| EPS in Rs | 21.54 | 20.95 | 6.32 | 15.79 | -4.72 | 15.37 | 12.34 | 23.30 | 22.33 | 21.69 | 13.04 | 17.95 | 15.17 |
| Metric | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 517 | 564 | 544 | 571 | 728 | 832 | 814 | 806 | 1,003 | 1,296 | 1,716 | 2,276 | 2,432 |
| Expenses | 528 | 547 | 506 | 525 | 657 | 711 | 678 | 719 | 838 | 1,111 | 1,462 | 2,014 | 2,202 |
| Operating Profit | -11 | 16 | 37 | 46 | 71 | 121 | 135 | 86 | 165 | 184 | 254 | 262 | 230 |
| OPM % | -2.2% | 2.9% | 7% | 8% | 10% | 15% | 17% | 11% | 16% | 14% | 15% | 12% | 9% |
| Other Income | 6 | 7 | 14 | 12 | 16 | 13 | 13 | 15 | -14 | 51 | -56 | 23 | 21 |
| Interest | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 4 | 6 |
| Depreciation | 15 | 17 | 16 | 15 | 15 | 19 | 20 | 17 | 16 | 15 | 40 | 29 | 17 |
| Profit before tax | -21 | 6 | 36 | 44 | 73 | 114 | 127 | 83 | 134 | 220 | 156 | 252 | 228 |
| Tax % | 0% | 9% | 44% | 41% | 25% | 37% | 27% | 26% | 26% | 26% | 26% | 26% | |
| Net Profit | -21 | 5 | 20 | 26 | 54 | 72 | 93 | 62 | 99 | 162 | 116 | 188 | 170 |
| EPS in Rs | -8.34 | 2.10 | 8.02 | 10.36 | 21.78 | 28.88 | 37.32 | 24.64 | 39.72 | 64.60 | 46.30 | 75.01 | 67.85 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 3% | 5% | 41% | 40% | 37% | 69% | 48% |
Growth — CAGR
| Metric | 3Y | 5Y | 10Y |
|---|---|---|---|
| Revenue CAGR | 31.0% | 23.0% | 15.0% |
| Profit CAGR | 15.0% | 16.0% | 43.0% |
Shareholding Pattern
Promoters75.00%
FIIs3.03%
DIIs4.55%
Public17.41%
Promoters75.00%
FIIs2.74%
DIIs5.26%
Public17.00%
Promoters75.00%
FIIs2.71%
DIIs5.55%
Public16.73%
Promoters75.00%
FIIs2.78%
DIIs5.79%
Public16.42%
Promoters75.00%
FIIs2.68%
DIIs6.08%
Public16.24%
Promoters75.00%
FIIs2.70%
DIIs1.41%
Public20.88%
Promoters75.00%
FIIs2.73%
DIIs3.77%
Public18.50%
Promoters75.00%
FIIs2.89%
DIIs4.65%
Public17.45%
Promoters75.00%
FIIs2.78%
DIIs5.79%
Public16.42%
Promoters75.00%
FIIs2.68%
DIIs6.08%
Public16.24%
ASTRAZEN
Holdings Analysis
Key strengths & risk signals
59
Overall
73
Fundamental
45
Technical
Risks (4)
LOW MARGIN! 7.0% profit margin - thin profits.
POOR YEAR! Stock declined 35.2% in the last year.
WEAK POSITION! Current price (5970.5) is below both moving averages.
WEAK! Trading at 7.9% of 52W range - near yearly lows.
Strengths (4)
PERFECT RECORD! Revenue has grown consistently every year. Exceptional business stability.
LOW VOLATILITY! Beta of 0.20 - stable stock, less market risk.
TESTING SUPPORT! Stock is at key support level.
APPROACHING OVERSOLD! RSI at 32.6 - watch for reversal.
Fundamental & Technical Analysis
59Overall
73Fundamental
45Technical
Fundamental Breakdown
Growth Quality
30/30
Revenue CAGR: 31.3% (EXCELLENT, 15/15). Profit CAGR: 23.6% (EXCELLENT, 15/15).
Profit Margin
3/10
LOW MARGIN! 7.0% profit margin - thin profits.
PEG Valuation
3/10
OVERVALUED! PEG of 3.73 means expensive relative to growth rate.
Dividend Yield
3/10
NEGLIGIBLE DIVIDEND! 0.61% yield - little to no income.
Debt to Equity
10/10
VERY LOW DEBT! D/E of 0.00 - excellent financial health.
Public Holding
14/20
MODERATE PUBLIC HOLDING! 20.4% public ownership - balanced ownership structure.
Stability Index
10/10
PERFECT RECORD! Revenue has grown consistently every year. Exceptional business stability.
Technical Breakdown
Moving Averages
5/10
BEARISH TREND! 50-day average (6854.5) is below 200-day average (8023.6) - negative signal.
Price Position
2/10
WEAK POSITION! Current price (5970.5) is below both moving averages.
Trend Pattern
16/20
TESTING SUPPORT! Stock is at key support level.
52W Performance
0/10
POOR YEAR! Stock declined 35.2% in the last year.
Volume Sentiment
10/30
BEARISH SENTIMENT! In last 30 days: 12 up days, 18 down days. Avg volume on up days: 7,174 vs down days: 11,613. Ratio: 0.62x
RSI
4/5
APPROACHING OVERSOLD! RSI at 32.6 - watch for reversal.
52W Range
1/5
WEAK! Trading at 7.9% of 52W range - near yearly lows.
Momentum
2/5
WEAK MOMENTUM! Limited price growth - 2.3% (1 week), -10.9% (1 month), -25.6% (3 months).
Beta
5/5
LOW VOLATILITY! Beta of 0.20 - stable stock, less market risk.
Peer Comparison
Healthcare · Drug Manufacturers - Specialty & Generic · 8 stocks
| Stock | Price | P/E | Profit Margin | Revenue CAGR 5Y | Profit CAGR 5Y | 52W Change | Stock Strength | Trendline | YoY Profit | QoQ Profit | YoY Revenue | QoQ Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASTRAZEN | ₹5,970.50 | 88 | 7.0% | 31.3% | 23.6% | -35.2% | 59 | BOUNCE FROM SUPPORT | -32.1% | -15.6% | +29.7% | +18.0% |
| JUBLPHARMA | ₹938.60 | 42.3 | 4.1% | 9.8% | – | -12.7% | 54 | BREAKDOWN | -45.1% | -52.7% | +18.2% | -2.2% |
| NATCOPHARM | ₹785.00 | 12.4 | 32.8% | 14.5% | 25.6% | -4.8% | 66 | APPROACHING SUPPORT | -57.0% | -22.9% | -44.7% | -0.5% |
| APLLTD | ₹789.50 | 22.4 | 8.9% | 9.5% | 25.4% | -15.5% | 72 | BREAKDOWN | +12.1% | -14.6% | +25.7% | +16.4% |
| ERIS | ₹1,144.40 | 24.4 | 20.0% | 23.3% | 17.5% | -28.0% | 66 | BOUNCE FROM SUPPORT | +20.7% | -49.4% | +12.6% | +15.5% |
| ALIVUS | ₹1,309.50 | 26.7 | 23.3% | 6.9% | 6.5% | +46.0% | 73 | BREAKDOWN | +31.8% | -1.6% | +6.4% | -7.1% |
| CAPLIPOINT | ₹2,301.30 | 26.4 | 29.1% | 14.3% | 19.4% | +17.6% | 76 | BREAKDOWN | +15.8% | +4.0% | +19.6% | +1.7% |
| COHANCE | ₹464.10 | 170 | 5.0% | 18.3% | -24.2% | -48.8% | 62 | HIT RESISTANCE | -149.3% | -223.0% | -23.1% | -31.8% |
Data from TradeAlone · Updated daily
ASTRAZEN News
Astrazeneca Pharma India Limited Q2 Fy26-27: 30% Growth, INR 7,291 Mn Revenue2026-11-05Astrazeneca Pharma India Limited (astrazen) Inaugurates New Mumbai Corporate Office, Marking Phase of Growth Through Innovation2026-10-16Astrazeneca Pharma India Limited (astrazen) Q1 Fy2026-27: Revenue Surges 30% to INR 6,828 Mn2026-08-11Astrazeneca Pharma India Limited (astrazen) Marks Consistent 33% Growth in FY 2025-262026-05-26
